| Name | Title | Contact Details |
|---|
Nationwide Better Health is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Healthcare industry veterans Joe Caruncho – whose success at the helm of Preferred Care Partners led to annual sales in excess of $750 million – and Orlando Lopez-Fernandez, Jr., MD, founded Genuine Health Group to usher in a new era of healthcare delivery focused on value instead of volume. Today, Genuine Health is building a model for managing care delivery that embodies traditional values, promises reliability, and embraces flexibility and technology. Through its accountable care organization, PremierMD ACO, the company aims to improve healthcare outcomes, achieve cost savings for the care of patients who receive traditional, fee-for-service Medicare benefits, and serve as a single point of contact to move doctors` Medicare members into value-based care. And, through its management service organization (MSO), the company aims to deliver financial upside for its participating physicians whose patients are enrolled in Medicare Advantage plans. For both traditional Medicare beneficiaries and those who choose managed care plans, Genuine Health and its providers are demonstrating the powerful effects of value-based care.
Discovery Institute of Medical Education is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cosmetic LaserWorks is a Beverly Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.